You make the medicine.
The park is your infrastructure.
Genesis Science Park is an Infrastructure-as-a-Service life sciences park. Instead of every manufacturer building and running its own power, water, effluent and GMP-grade infrastructure, and carrying the full cost and risk of doing so alone, the park provides that layer as a shared service, so a member can put its capital and attention into what actually makes it money - producing medicine to standard. It is the difference between buying a plant and buying the ability to manufacture.
Members join a purpose-built life sciences environment and receive the infrastructure layer that a pharmaceutical facility cannot operate without, delivered as a service rather than building from scratch.
GMP-ready facilities and clean utilities
Building facilities and shared clean utilities (clean steam, compressed air, nitrogen) designed for cleanroom classification and qualification
Facilities maintenance
Maintenance of the shared infrastructure and estate systems, so continuity is managed at park level rather than falling to each tenant’s team
Waste management
Coordinated handling of general and controlled waste streams at estate level (distinct from your own qualified process effluent, which remains yours)
Power engineered for pharmaceutical continuity
Uninterrupted, redundant supply that GMP manufacturing requires, provided at park scale rather than self-generated plant by plant
Pharmaceutical-grade water infrastructure
The supply and treatment backbone for purified water and Water-for-Injection systems
Compliant effluent handling
Treatment and discharge infrastructure to environmental standard, the constraint that disqualifies many standalone sites
On-site security
Estate-level security infrastructure and management, shared across the park rather than stood up by each manufacturer
A life sciences specific site
Engineered on a site selected against the criteria that decide whether a pharmaceutical plant can operate economically at all
Regulatory and compliance one-stop shop
A single point of coordination for regulatory and compliance submissions, helping members move through approvals with less friction
You retain and control everything that touches your product: your own qualified systems, your process, your quality function and your regulatory identity. What is shared is the supply of infrastructure, not the manufacturing itself.
Founding and qualified members also gain strategic support that extends well beyond day-to-day operations including help accessing the kind of international capital and funding this sector depends on, and which most Nigerian manufacturers cannot reach alone. How that support works, and the specific programmes it opens, is set out during the prospectus conversation rather than published here which is one reason the most serious manufacturers engage early.
The part of your feasibility study we’ve taken care of
No need to build alone, pay for it alone operate alone.
The largest, least financeable and most operationally demanding burdens - power, water and effluent - removed from your balance sheet converting infrastructure capex into opex. (See why these dominate cost on our cost of an API plant and infrastructure pages.)
Our model lets you be a manufacturer not an utility operator freeing capital and scarce technical management for production and quality.
The park starts you on a site that already answers the siting criteria. (See the eight criteria on our siting page.) The location work that most projects defer to feasibility is done upstream.
As an SPV, at concept level, members are not simply tenants renting space from a landlord whose interests differ from theirs, you participate in the vehicle that develops and operates the park so incentives are aligned around the park working for the manufacturers inside it.
Early members are founding members taking anchor positions, helping shape the park around real manufacturing requirements and engage on founding terms. This includes priority capacity/plot allocation, locked founding tariffs for a defined period, right of first refusal on expansion land, build to spec for phase one, and MFN protection.
If you have completed a feasibility study, or you are operational and expanding, the prospectus is where the detail lives.
→ Express your interest and receive the technical prospectus.
Our model structure
FAQs
Co-locating does create a dependency, and you should understand the participation and exit terms fully before committing to anything, that is exactly what the prospectus and the conversation after it are for. But the commitment is to shared infrastructure, not to surrendering control of your plant - your qualified systems, process, quality function and licences remain yours. And the consortium to SPV structure is specifically designed so a member can be a participant in the vehicle rather than a captive tenant of a landlord. The founding stage is also when terms are most shapeable, which is the opposite of a take it or leave it lease.
Utilisation risk is real in any shared infrastructure model, and you are right to probe it. It is the precise reason the park is being validated before it is built rather than after. The expression of interest process exists to confirm real demand and size the park to it, instead of constructing speculatively and hoping manufacturers appear. That demand first sequence is what distinguishes this from projects that break ground on a masterplan and stall. Founding and anchor members further de-risk early utilisation.
No, and you should treat early engagement as exactly that ‐ early. Expressing interest is not a commitment to build, buy or sign, it’s a validation signal that unlocks the prospectus and opens a conversation. Founding members shape a project as it forms, they do not gamble on a finished thing. We report progress honestly through a public milestone tracker precisely so you can judge momentum for yourself rather than take our word for it.
Because a general industrial park landlord has no obligation to build to WHO GMP standard, and a lease gives you no say in how the site evolves around your needs. The SPV structure exists specifically so manufacturers help shape the park’s infrastructure, tariffs and expansion around real pharmaceutical requirements, with incentives aligned toward tenants succeeding rather than a landlord simply collecting rent.
Yes, and for some manufacturers that is the right decision. Our model is not for everyone. If you build standalone, you carry the full infrastructure capital cost, the permanent burden of operating utilities to pharmaceutical reliability, and the waste of redundancy sized for one plant, alone. Genesis is for manufacturers who would rather put their capital and their scarce technical management into product and quality than into becoming a power company. The real test is whether infrastructure is your competitive advantage or your overhead. If it’s overhead, sharing it is the rational choice.